- Home
- AGIO vs TNDM Comparison
AGIO vs TNDM Comparison
Compare AGIO & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- TNDM
- Stock Information
- Founded
- AGIO 2007
- TNDM 2006
- Country
- AGIO United States
- TNDM United States
- Employees
- AGIO N/A
- TNDM N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- TNDM Medical/Dental Instruments
- Sector
- AGIO Health Care
- TNDM Health Care
- Exchange
- AGIO Nasdaq
- TNDM Nasdaq
- Market Cap
- AGIO 2.4B
- TNDM 2.7B
- IPO Year
- AGIO 2013
- TNDM 2013
- Fundamental
- Price
- AGIO $41.33
- TNDM $41.78
- Analyst Decision
- AGIO Hold
- TNDM Buy
- Analyst Count
- AGIO 5
- TNDM 15
- Target Price
- AGIO $52.50
- TNDM $53.27
- AVG Volume (30 Days)
- AGIO 585.1K
- TNDM 1.1M
- Earning Date
- AGIO 10-31-2024
- TNDM 11-06-2024
- Dividend Yield
- AGIO N/A
- TNDM N/A
- EPS Growth
- AGIO N/A
- TNDM N/A
- EPS
- AGIO N/A
- TNDM N/A
- Revenue
- AGIO $31,306,000.00
- TNDM $796,002,000.00
- Revenue This Year
- AGIO $44.80
- TNDM $21.53
- Revenue Next Year
- AGIO $174.95
- TNDM $11.81
- P/E Ratio
- AGIO N/A
- TNDM N/A
- Revenue Growth
- AGIO 55.39
- TNDM 0.72
- 52 Week Low
- AGIO $19.80
- TNDM $13.82
- 52 Week High
- AGIO $53.29
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- AGIO 37.77
- TNDM 45.90
- Support Level
- AGIO $40.37
- TNDM $39.92
- Resistance Level
- AGIO $46.24
- TNDM $45.28
- Average True Range (ATR)
- AGIO 2.35
- TNDM 2.39
- MACD
- AGIO -0.66
- TNDM -0.38
- Stochastic Oscillator
- AGIO 7.39
- TNDM 26.88
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.